Please login to the form below

Not currently logged in
Email:
Password:

CAR-T therapies

This page shows the latest CAR-T therapies news and features for those working in and with pharma, biotech and healthcare.

Poseida gets Novartis backing for myleoma CAR-T challenger

Poseida gets Novartis backing for myleoma CAR-T challenger

Novartis. The San Diego-based start-up company has developed a range of non-viral gene engineering technologies to create a pipeline of autologous CAR-T therapies, with its lead candidate ... in single-treatment cures for numerous oncologic indications

Latest news

  • Catalent preps for complex therapy boom with $1.2bn Paragon buy Catalent preps for complex therapy boom with $1.2bn Paragon buy

    Reflects growing investment in cell and gene therapies. Catalent has agreed a deal to buy Paragon Bioservices, a contract development and manufacturing organisation that specialises in complex biopharmaceuticals. ... viruses and CAR-T cell therapies,

  • Autolus’ next-gen CAR-T looks promising in ALL Autolus’ next-gen CAR-T looks promising in ALL

    Autolus is hoping that AUTO1 will change that, and its first wave of data from that programme found it compared favourably to other CAR-T therapies in adult ALL. ... They pointed out that severe CRS is “significantly hampering the treatment of ALL with

  • GSK’s myeloma drug hits target, prompting rapid filing pledge GSK’s myeloma drug hits target, prompting rapid filing pledge

    The product will be vying for market share against a slew of other pipeline competitors in BCMA- targeting therapies in multiple myeloma including a CAR-T treatment from Celgene and Bluebird ... Celgene and Bluebird’s CAR-T bb2121 is currently seen as

  • NICE wants to stop saying ‘no’ – but needs pharma’s co-operation NICE wants to stop saying ‘no’ – but needs pharma’s co-operation

    industry. Recent examples of this include rapid pricing deals on the two CAR-T therapies, Novartis’ Kymriah and Gilead’s Yescarta. ... This includes cell and gene therapies such as Novartis’ late-stage candidate Zolgensma, which the company has

  • NICE partially clears Darzalex combo in blood cancer NICE partially clears Darzalex combo in blood cancer

    When used in combination with Velcade and corticosteroid medication dexamethasone, those taking Darzalex achieved an extended progression free survival of 18 months compared to existing therapies. ... Myeloma is an increasingly dynamic and competitive

More from news
Approximately 3 fully matching, plus 58 partially matching documents found.

Latest Intelligence

  • Cell and gene therapy Cell and gene therapy

    In addition, as Eric Althoff from Swiss pharmaceutical firm Novartis points out, making a patient-specific product like a CAR-T therapy is very different from producing a volume drug. ... Manufacturing of CAR-T cell therapies is a highly sophisticated,

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    TALEN is now being deployed most widely in chimeric antigen receptor T cell (CAR-T) therapies, which generally involve harvesting T cells from patients, modifying them to attack tumour cells by ... Companies like Cellectis and partner Allogene are

  • Cutting through the noise: CRISPR Cutting through the noise: CRISPR

    Scientists can then examine the effect of this change, uncovering potential disease targets for therapies. ... It’s very difficult to systemically deliver a CRISPR therapeutic selectively to the right place, especially when there are easier ways of

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene ... oral therapies such as Tyk inhibitors from Bristol-Myers Squibb

  • China’s clinical trial shake-up China’s clinical trial shake-up

    Once seen as a manufacturer of generics rather than a developer of innovative drugs, China is now involved in half of all enrolling cancer trials of CAR-T cell therapies.

More from intelligence
Approximately 0 fully matching, plus 18 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Highlights in haematologic malignancy from ASH 2018

    However, CAR T-cell therapies stop working in some patients and severe toxicity can also occur. ... Other abstracts reported on CAR T-cell therapies for multiple myeloma directed against the B-cell maturation antigen (BCMA).

  • Download our infographic: Addressing the biggest challenges for rare disease communities

    Recently these have included advanced genetic therapies, such as viral mediated gene transfer and CAR-T therapies.

  • Training the next generation of biotech leaders

    In this year alone, the FDA has taken the groundbreaking step of approving two CAR-T therapies. ... The approval of two CAR-T therapies this year illustrates how cell and gene therapies are turning from scientific dream to reality, with companies in the

  • Addressing the biggest challenges for rare disease communities

    It is common that primary care physicians either do not recognise specific symptoms or don’t make the link between common symptoms and a rare disease. ... year, we saw landmark breakthroughs in advanced genetic therapies, such as viral mediated gene

  • Ashfield

    Recently these have included advanced genetic therapies, such as viral mediated gene transfer and CAR-T therapies. ... Whether we’re buying something as simple as a toaster or as expensive as a new car, we’ve all come to expect fantastic service at

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics